New drug zanidatamab aims to shrink early breast cancer tumors before surgery
NCT ID NCT05035836
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial is testing a drug called zanidatamab in 20 people with early-stage, low-risk HER2-positive breast cancer. The drug is given intravenously, along with hormone therapy pills (letrozole or tamoxifen). The main goal is to see if the cancer disappears completely by the time of surgery. The study is currently recruiting at a single site.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanidatamab (also called ZW25), given intravenously, along with letrozole or tamoxifen pills
What this could lead to
If it works, this could point toward a new treatment option for early-stage HER2+ breast cancer that may reduce the need for chemotherapy.
What could go wrong
This is a very small, early-phase trial with only 20 participants and no comparison group. The drug may not work as hoped, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.